Cure8 news brief
Shattuck Labs plans to advance a DR3-targeting bispecific antibody (SL-325) into a Phase 2b trial for Crohn's disease, which is relevant to people watching new investigational biologics for IBD. The report is a development/timeline update rather than clinical results.
patients and caregivers interested in experimental biologics for Crohn's disease or UC; clinicians and researchers following DR3-targeting therapies; investors tracking biotech pipelines
Shattuck Labs reported Q2 financials and said it plans to start a Phase 2b trial (RECEPTIVE-CD1) of SL-325 for moderate-to-severe Crohn's disease in Q3 2026.
The company also noted SL-325 is in a Phase 1 program (including ulcerative colitis among indications) and that another candidate, SL-846, is in GLP toxicology with Phase 1 dosing planned and initial data expected in 2027. This item is a business/clinical development update rather than clinical results.
It may matter for people tracking new investigational therapies or following Shattuck Labs as a company, but it does not provide efficacy or safety findings and does not change current treatment guidance.
patients and caregivers interested in emerging biologic therapies for Crohn's disease and ulcerative colitis, clinicians and researchers following DR3-targeting antibodies, and investors tracking biotech development timelines. this is a company press/business report about planned trials and financial results.
The announcement describes trial starts and development plans, not trial outcomes; timing and plans can change.
This article is a financial/clinical development news piece from RTTNews summarizing company statements. It reports planned trial starts and program milestones but does not include clinical data. Timelines for INDs and trial initiations are subject to change.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The article reports new phase 2 trial data for duvakitug, an experimental anti‑TL1A treatment for ulcerative colitis and Crohn’s disease, which helps compare it to rival candidates and shapes upcoming phase 3 plans.
If PALI-2108 proves safe and effective in Phase 2 trials, it could add a new oral treatment option for people with ulcerative colitis and Crohn’s disease. Early Phase 1 signals and a funded Phase 2 program mean the...
If you or a loved one follow emerging IBD treatments, this update signals a new PALI-2108 program moving into Phase 2 for ulcerative colitis and planned Phase 2 testing in Crohn’s disease, plus a company focus on...
